Salman Tarik, Demir Leyla, Varol Umut, Akyol Murat, Oflazoglu Utku, Yildiz Yasar, Taskaynatan Halil, Cengiz Hakan, Guvendi Guven, Kucukzeybek Yuksel, Alacacioglu Ahmet, Tarhan Oktay
Katip Celebi University, Ataturk Research and Training Hospital, Department of Medical Oncology, Izmir, Turkey.
J BUON. 2016 Nov-Dec;21(6):1419-1424.
The adipose tissue plays a role in carcinogenesis with the adipokines it generates. Apelin is an anti-obesigenic adipokine, and assumes roles in both vascularization and tumor cell proliferation. The present study aimed to investigate changes in apelin levels, in postmenopausal breast cancer (BC) patients receiving aromatase inhibitors (AIs).
Forty early-stage postmenopausal BC patients treated with AIs with no history of chemotherapy administration were included in the study. At the beginning, we measured serum apelin levels in postmenopausal BC patients who were receiving AIs and healthy women of similar age and normal body mass index (BMI) (control group). We evaluated changes in the body composition, serum lipid profile and serum apelin levels at the beginning and the 12th month through anthropometric measurements and bioelectric impedance analysis.
Forty subjects with postmenopausal BC had a median age of 57 years (range 44-82)). BC patients exhibited significantly higher apelin levels and body mass index (BMI) scores compared to the control group (p=0.0001, p=0.0001, respectively). The 12th month's measurements indicated reduced apelin levels in 24 patients (60%) and increased apelin levels in 16 patients (40%) compared to the initial figures. With respect to the parameters, the patients with reduced apelin levels had significantly different waist-to-hip ratio (WHR) and fat mass scores compared to those with higher apelin levels (p=0.008, p=0.047, respectively).
This study showed that postmenopausal BC patients had high levels of apelin and high BMI scores. This finding suggests that apelin promoted carcinogenesis particularly in obese individuals. The massive and metabolic changes observed in the fat tissues of the postmenopausal BC patients receiving AIs will especially affect the BC-associated outcome.
脂肪组织通过其产生的脂肪因子在致癌过程中发挥作用。Apelin是一种抗肥胖脂肪因子，在血管生成和肿瘤细胞增殖中均起作用。本研究旨在调查接受芳香化酶抑制剂（AIs）治疗的绝经后乳腺癌（BC）患者中Apelin水平的变化。
本研究纳入了40例接受AIs治疗且无化疗史的早期绝经后BC患者。开始时，我们测量了接受AIs治疗的绝经后BC患者以及年龄相仿、体重指数（BMI）正常的健康女性（对照组）的血清Apelin水平。通过人体测量和生物电阻抗分析，我们评估了研究开始时和第12个月时的身体成分、血清脂质谱和血清Apelin水平的变化。
40例绝经后BC患者的中位年龄为57岁（范围44 - 82岁）。与对照组相比，BC患者的Apelin水平和体重指数（BMI）得分显著更高（分别为p = 0.0001，p = 0.0001）。与初始数据相比，第12个月的测量结果显示，24例患者（60%）的Apelin水平降低，16例患者（40%）的Apelin水平升高。在各项参数方面，Apelin水平降低的患者与Apelin水平较高的患者相比，腰臀比（WHR）和脂肪量得分有显著差异（分别为p = 0.008，p = 0.047）。
本研究表明，绝经后BC患者的Apelin水平较高且BMI得分较高。这一发现表明，Apelin尤其在肥胖个体中促进致癌作用。接受AIs治疗的绝经后BC患者脂肪组织中观察到的大量代谢变化将特别影响与BC相关的结局。
